Congressional action BIO wants to see in 2024
As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year. BIO’s …
Loss of tax incentive for R&D threatens biotech innovation
After two decades of research and development, Sutro Biopharma is still a few years away from seeking market approval for its first drug, a …
Loss of tax incentive for R&D threatens biotech innovation Read More »
FTC’s aggressive questions on patents registered with FDA is harmful overreach, expert says
The Federal Trade Commission (FTC) challenge of more than 100 patent listings registered with the Food and Drug Administration, mostly for devices used to …
Proposed EU Pharma Law features good intentions and bad ideas, says BIO-Europe panel
The proposed updated European Union General Pharmaceutical Legislation offers some opportunities but also creates some new threats for biotech—and when it becomes law in …
Proposed EU Pharma Law features good intentions and bad ideas, says BIO-Europe panel Read More »
M&A activity a bright spot in funding for biotech, expert tells 2023 BIO-Europe
As weakening investment plagues small, innovative biotechs on both sides of the Atlantic, one bright spot in providing funding is acquisitions—though even that vital …
M&A activity a bright spot in funding for biotech, expert tells 2023 BIO-Europe Read More »
Bill seeks accurate measures of how well biofuels cut carbon emissions
A bill to incentivize production of low-carbon biofuels by ensuring that the environmental benefits of these fuels are measured accurately when assessing tax credits …
Bill seeks accurate measures of how well biofuels cut carbon emissions Read More »
FTC plans for aggressive merger enforcement threaten biotech innovation, BIO says
Federal Trade Commission (FTC) proposals for new rules to permit more aggressive opposition to mergers would interfere with the economic ecosystem that is essential …
FTC plans for aggressive merger enforcement threaten biotech innovation, BIO says Read More »
Top legal experts: Laws protecting IP aren’t tools for drug price controls
Legislation to encourage innovation and protect patent holders should not be distorted into instruments for drug price controls, a high-profile group of former judges, …
Top legal experts: Laws protecting IP aren’t tools for drug price controls Read More »
Battling sepsis and superbugs requires awareness and policy
Generated by our own internal defenses, sepsis claims 350,000 adult lives each year in the United States and is the most costly condition behind …
Battling sepsis and superbugs requires awareness and policy Read More »
BIO Vice Chair John F. Crowley to Congress: IRA reduces access to innovative drugs
Drug price controls in the Inflation Reduction Act (IRA) harm the development of new drugs, according to Sept. 20 testimony in Congress from John …
BIO Vice Chair John F. Crowley to Congress: IRA reduces access to innovative drugs Read More »